Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2013-000860-27 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a two-part, multicenter, open label, non-randomized, phase Ib/II study to assess the safety and tolerability, Maximum Tolerated Dose and preliminary efficacy of Givinostat in patients with JAK2V617F positive Polycythemia Vera. Part A is the dose finding part while Part B is assessing the preliminary efficacy. Patients will be enrolled either in Part A or Part B and transition from one part to the other is not allowed.
Eligible patients for this study will have a confirmed diagnosis of Polycythemia Vera according to the revised World Health Organization criteria. Only if the enrolment in Part A is slow (i.e. < 5 patients enrolled in 3 months), eligibility for this part of the study may be expanded to all patients with chronic myeloproliferative neoplasms.
Study therapy will be administered in 28 day cycles (4 weeks of treatment). Disease response will be evaluated according to the European LeukemiaNet criteria after 3 and 6 cycles (i.e. at weeks 12 and 24, respectively) of treatment with Givinostat for both parts of the study. All phlebotomies performed in the first 3 weeks of treatment will not be counted to assess the clinico-haematological response.
The study will last up to a maximum of 24 weeks of treatment. However, after completion of the trial, all patients achieving clinical benefit will be allowed to continue treatment with Givinostat (at the same dose and schedule) in a long-term study.
Safety will be monitored at each visit throughout the entire duration of the study. Treatment will be administered on an outpatient basis and patients will be followed regularly with physical and laboratory tests, as specified in the protocol; in case of hospitalization, the treatment will be continued or interrupted according to the Investigators' decision.
This is a two-part, multicenter, open label, non-randomized, phase Ib/II study to assess the safety and tolerability, MTD and preliminary efficacy of Givinostat in patients with JAK2V617F positive PV.
Part A is the dose escalation portion of the study and, once the MTD has been established, Part B will commence where the preliminary efficacy of Givinostat in PV patients will be established. Patients will be enrolled either in Part A or Part B and transition from one part to the other is not allowed. Only PV patients from Part A assigned to the dose selected for Part B (MTD) may be counted towards the efficacy assessment in Part B.
Eligible patients for this study will have a confirmed diagnosis of PV according to the revised WHO criteria and the JAK2V617F positivity. Only if the enrolment in Part A is slow (i.e. < 5 patients enrolled in 3 months), eligibility for this part of the study may be expanded to all patients with cMPN.
After providing informed written consent before undertaking any protocol-related procedure, a unique patient identification code (i.e. patient screening ID which will be a combination of his/her site ID, study part ID and patient screening number, e.g. IT01-A01) will be assigned to each patient and it will identify the patient within his/her enrolment confirmation by Italfarmaco S.p.A. or its designee and never be reused in case of screening failure. After the enrolment confirmation and the assignation of the dose level before the first drug intake, a unique patient identification code (i.e. patient ID which will be a combination of patient screening number ID and dose level ID, e.g. IT01-A01-DL1) will be assigned to each patient and it will identify the patient throughout his/her participation in the study and never be reused in case of premature drop-out.
Study therapy will be administered in 28 day cycles. In fact, the "cycle" is defined as 4 weeks of treatment.
Disease response will be evaluated according to the clinico-haematological ELN criteria after 3 and 6 cycles (i.e. at weeks 12 and 24, respectively) of treatment with Givinostat for both parts of the study. All phlebotomies performed in the first 3 weeks of treatment will not be counted to assess the clinico-haematological response.
The study will last up to a maximum of 24 weeks of treatment. However, after completion of the trial, all patients achieving clinical benefit will be allowed to continue treatment with Givinostat (at the same dose and schedule) in a long-term study (Study N.: DSC/11/2357/44).
Safety will be monitored at each visit throughout the entire duration of the study. Treatment will be administered on an outpatient basis and patients will be followed regularly with physical and laboratory tests, as specified in the protocol; in case of hospitalization, the treatment will be continued or interrupted according to the Investigators' decision.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Givinostat | Experimental | In Part A patients will treated in dose levels at the following daily doses of Givinostat:
In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Givinostat | Drug | In Part A patients will treated in dose levels at the following daily doses of Givinostat:
In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in Part A of the Study | Evaluations were performed on the type, incidence and severity of TEAEs, graded according to Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03, following administration of givinostat for up to 6 cycles of treatment in Part A. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / treatment-emergent serious adverse event (TESAE) corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment. | 168 days (up to Cycle 6 Day 28 in Part A). |
| Number of Dose Limiting Toxicities (DLTs) After 1 Cycle in Part A of the Study | The MTD of givinostat was based only on Cycle 1 DLTs. A DLT was defined as the following drug-related toxicity:
At end of Cycle 1, for the third patient in each DL, the safety of the 3 patients treated for 1 cycle was reviewed and it was decided if the dose should be escalated or not. Results are reported as the number of patients with DLT events for Cycle 1 in Part A. | 28 days (up to Cycle 1 Day 28 in Part A). |
| Number of Patients Experiencing TEAEs After 3 Cycles in Part B of the Study | Evaluations were performed on the type, incidence and severity of TEAEs, graded according to CTCAE v. 4.03, following administration of givinostat at the MTD for up to 3 cycles of treatment in Part B. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / TESAE corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| ORR After 3 Cycles and After 6 Cycles in Part A of the Study | ORR following administration of givinostat after 3 cycles and after 6 cycles in Part A, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological ELN response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. Analysis performed using the dataset for all Part A patients combined. |
Not provided
Inclusion Criteria:
Patients must be able to provide informed consent and be willing to sign an informed consent form;
Patients must have an age ≥18 years;
Patients must have a confirmed diagnosis of Polycythemia Vera according to the revised World Health Organization criteria;
Patients must have mutated Janus Kinase 2 (mutation V617F) positive disease;
Patients must have an active/not controlled disease defined as
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 in Part A, ECOG performance status ≤ 2 in Part B within 7 days of initiating study drug;
Female patient of childbearing potential has a negative serum or urine pregnancy test within 72 hours of the first dose of study therapy;
Use of an effective means of contraception for women of childbearing potential and men with partners of childbearing potential;
Adequate and acceptable organ function within 7 days of initiating study drug;
Willingness and capability to comply with the requirements of the study.
Note that if the enrolment in Part A is slow (i.e. < 5 patients enrolled in 3 months), eligibility for this part of the study may be expanded to all patients with chronic myeloproliferative neoplasms. In this case, the inclusion criteria 5 will be modified as following only for Part A:
5. Patients must have an active/not controlled disease defined as:
Exclusion Criteria:
Active bacterial or mycotic infection requiring antimicrobial treatment;
Pregnancy or nursing;
A clinically significant corrected QT interval prolongation at baseline;
Use of concomitant medications known to prolong the corrected QT interval;
Clinically significant cardiovascular disease including:
Known positivity for human immunodeficiency;
Known active hepatitis B virus and/or hepatitis C virus infection;
Platelet count < 100 x109/L within 14 days before enrolment;
Absolute neutrophil count < 1.2x109/L within 14 days before enrolment;
Serum creatinine > 2 times the upper limit of normal;
Total serum bilirubin > 1.5 times the upper limit of normal except in case of Gilbert's disease;
Serum aspartate aminotransferase/alanine aminotransferase (AST/ALT) > 3 times the upper limit of normal;
History of other diseases (including active tumours), metabolic dysfunctions, physical examination findings, or clinical laboratory findings giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications;
Prior treatment with a Janus Kinase 2 or Histone Deacetylase inhibitor or participation in an interventional clinical trial for chronic myeloproliferative neoplasms;
Systemic treatment for chronic myeloproliferative neoplasms other than aspirin/cardio aspirin;
Hydroxyurea within 28 days before enrolment;
Interferon alpha within 14 days before enrolment;
Anagrelide within 7 days before enrolment;
Any other investigational drug or device within 28 days before enrolment;
Patient with known hypersensitivity to the components of study therapy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Paolo Bettica, MD | Italfarmaco S.p.A. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU Amiens - Hôpital Sud | Amiens | 80054 | France | |||
| Hôpital Morvan - CHRU de Brest |
Patients were enrolled into either Part A or Part B, transition from 1 part to the other was not allowed. 48 patients were enrolled into the study overall: 12 patients in Part A to determine the maximum tolerated dose (MTD) and 36 patients in Part B.
This was a 2-part, multisite, open-label, non-randomized study to assess givinostat in patients with JAK2^V617F positive Polycythemia Vera. Part A assessed safety and was the dose escalation portion of study, while Part B assessed preliminary efficacy. Patients were enrolled in 5 countries (France, Germany, Italy, Poland and the United Kingdom).
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Givinostat DL0 (50 mg b.i.d.) (Part A) | In Part A, 3 patients were assigned to receive givinostat by oral administration at Dose Level 0 (DL0) (50 milligrams [mg] twice daily [b.i.d.]). Patients were treated for up to 6 cycles (28 days in each cycle). There were 3 DLs used during Part A; 50 mg b.i.d. (DL0) was the third DL to be administered. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| SAP | No | Yes | No | Statistical Analysis Plan | Mar 21, 2018 | Mar 18, 2019 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| 84 days (up to Cycle 3 Day 28 in Part B). |
| Overall Response Rate (ORR) (i.e. Complete Response [CR] and Partial Response [PR]) After 3 Cycles in Part B of the Study | ORR, CR and PR following administration of givinostat at MTD for 3 cycles in Part B, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological European LeukemiaNet (ELN) response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. CR defined as:
PR defined as: Patients not fulfilling CR and
| 84 days (up to cycle 3 Day 28 in Part B). |
| 84 and 168 days (up to Cycle 3 Day 28 and Cycle 6 Day 28 in Part A). |
| ORR After 6 Cycles in Part B of the Study | ORR following administration of givinostat at the MTD for 6 cycles in Part B, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological ELN response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. | 168 days (up to Cycle 6 Day 28 in Part B). |
| Number of Patients Experiencing TEAEs After 6 Cycles in Part B of the Study | Evaluations were performed on the type, incidence and severity of TEAEs, graded according to CTCAE v. 4.03, following administration of givinostat at the MTD for up to 6 cycles of treatment in Part B. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / TESAE corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment. Results are reported as number of patients with TEAEs for each of the indicated categories. | 168 days (up to Cycle 6 Day 28 in Part B). |
| Assessment of Maximum Plasma Concentration (Cmax) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study | Pharmacokinetic (PK) evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Cmax following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis. | Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| Assessment of Time to Maximum Plasma Concentration (Tmax) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tmax following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis. | Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| Assessment of Time of the Last Detectable Concentration (Tlast) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tlast following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis. | Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| Assessment of Area Under Plasma Concentration Versus the Time Curve up to the Last Detectable Concentration (AUClast) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUClast following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis. | Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| Assessment of Area Under Plasma Concentration Versus the Time Curve in the Dosing Interval (0-12 Hours) (AUC0-12) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUC0-12 following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis and AUC0-12 was calculated using the linear trapezoidal rule. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note:concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) across all dose groups and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis. | Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| Assessment of Cmax of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Cmax following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis. | Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| Assessment of Tmax of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tmax following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis. | Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| Assessment of Tlast of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tlast following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis. | Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| Assessment of AUClast of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUClast following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis. | Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| Assessment of AUC0-12 of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUC0-12 following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2374 (Cycle 1 Day 28) across all dose groups and for ITF2375 in the 50 mg b.i.d. dose group was not available for PK analysis. | Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| Brest |
| 29609 |
| France |
| Hopital Saint Vincent de Paul - GHICL Lille | Lille | 59020 | France |
| Hôpital Saint-Louis (AP-HP), Centre Investigations Cliniques | Paris | 75475 | France |
| Charite Research Organisation GmbH | Berlin | 10117 | Germany |
| Universitaetsklinikum Koeln | Cologne | 50937 | Germany |
| Universitaetsklinikum Carl Gustav Carus TU Dresden | Dresden | 01307 | Germany |
| Universitaetsklinikum Freiburg | Freiburg im Breisgau | 79106 | Germany |
| Azienda ospedaliero universitaria Consorziale Policlinico di Bari | Bari | BA | 70124 | Italy |
| Azienda Ospedaliera Papa Giovanni XXIII | Bergamo | BG | 24127 | Italy |
| Azienda Ospedaliero-Universitaria Careggi, Florence | Florence | FI | 50134 | Italy |
| Fondazione IRCCS Policlinico San Matteo | Pavia | PV | 27100 | Italy |
| Istituto Tumori Giovanni Paolo II - IRCCS Ospedale Oncologico di Bari | Bari | 70124 | Italy |
| Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico | Milan | Italy |
| Università degli Studi di Napoli Federico II, Facoltà di Medicina e Chirurgia | Naples | 80131 | Italy |
| Ospedale Civile dello Spirito Santo | Pescara | Italy |
| Azienda Ospedaliero Universitaria Pisana | Pisa | 56126 | Italy |
| Azienda Ospedaliera "Bianchi-Melacrino-Morelli" | Reggio Calabria | 89125 | Italy |
| Università Campus Bio-Medico di Roma | Rome | Italy |
| Ospedale San Bortolo di Vicenza | Vicenza | 36100 | Italy |
| SP ZOZ Zespol Szpitali Miejskich w Chorzowie | Chorzów | 41-500 | Poland |
| Uniwersyteckie Centrum Kliniczne | Gdansk | 80-952 | Poland |
| Belfast City Hospital | Belfast | BT9 7BL | United Kingdom |
| Royal London Hospital | London | E1 1BB | United Kingdom |
| Royal Cornwall Hospital | Truro | TR1 3LJ | United Kingdom |
| FG001 |
| Givinostat DL1 (100 mg b.i.d.) (Part A) |
In Part A, 3 patients were assigned to receive givinostat by oral administration at DL1 (100 mg b.i.d.). Patients were treated for up to 6 cycles (28 days in each cycle). There were 3 DLs used during Part A; 100 mg b.i.d. (DL1) was the initial DL to be administered. |
| FG002 | Givinostat DL1 Expanded (100 mg b.i.d.) (Part A) | Following initial assignment of 3 patients to DL1 in Part A, a further 3 patients were assigned to DL1 so this treatment group is referred to as "DL1 expanded" (patients received givinostat by oral administration at 100 mg b.i.d.). Patients were treated for up to 6 cycles (28 days in each cycle). There were 3 DLs used during Part A; 100 mg b.i.d. (DL1) was the initial DL to be administered. |
| FG003 | Givinostat DL6 (100 mg + 50 mg) (Part A) | In Part A, 3 patients were assigned to receive givinostat by oral administration at DL6 (100 mg in the morning and 50 mg in the evening, i.e. 12 hours after). Patients were treated for up to 6 cycles in (28 days in each cycle). There were 3 DLs used during Part A; 100 mg + 50 mg (DL6) was the second DL to be administered. |
| FG004 | Givinostat at MTD (100 mg b.i.d.) (Part B) | In Part B, patients were assigned to receive the starting dose of givinostat by oral administration at the MTD determined in Part A (i.e. 100 mg b.i.d.). Patients were treated for up to 6 cycles (28 days in each cycle). Based on evaluations performed as part of the visit procedures on Day 28 of each cycle up to Cycle 5 and/or in any necessary additional study visit, the givinostat dose was decreased if appropriate for any patients that met dose reduction criteria. |
| Received Study Drug |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
The overall baseline population consists of all enrolled patients in either Part A or Part B of the study.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Givinostat DL0 (50 mg b.i.d.) (Part A) | In Part A, 3 patients were assigned to receive givinostat by oral administration at DL0 (50 mg twice daily [b.i.d.]). Patients were treated for up to 6 cycles (28 days in each cycle). There were 3 DLs used during Part A; 50 mg b.i.d. (DL0) was the third DL to be administered. |
| BG001 | Givinostat DL1 (100 mg b.i.d.) (Part A) | In Part A, 3 patients were assigned to receive givinostat by oral administration at DL1 (100 mg b.i.d.). Patients were treated for up to 6 cycles (28 days in each cycle). There were 3 DLs used during Part A; 100 mg b.i.d. (DL1) was the initial DL to be administered. |
| BG002 | Givinostat DL1 Expanded (100 mg b.i.d.) (Part A) | Following initial assignment of 3 patients to DL1 in Part A, a further 3 patients were assigned to DL1 so this treatment group is referred to as "DL1 expanded" (patients received givinostat by oral administration at 100 mg b.i.d.). Patients were treated for up to 6 cycles (28 days in each cycle). There were 3 DLs used during Part A; 100 mg b.i.d. (DL1) was the initial DL to be administered. |
| BG003 | Givinostat DL6 (100 mg + 50 mg) (Part A) | In Part A, 3 patients were assigned to receive givinostat by oral administration at DL6 (100 mg in the morning and 50 mg in the evening, i.e. 12 hours after). Patients were treated for up to 6 cycles in (28 days in each cycle). There were 3 DLs used during Part A; 100 mg + 50 mg (DL6) was the second DL to be administered. |
| BG004 | Givinostat at MTD (100 mg b.i.d.) (Part B) | In Part B, patients were assigned to receive the starting dose of givinostat by oral administration at the MTD determined in Part A (i.e. 100 mg b.i.d.). Patients were treated for up to 6 cycles (28 days in each cycle). Based on evaluations performed as part of the visit procedures on Day 28 of each cycle up to Cycle 5 and/or in any necessary additional study visit, the givinostat dose was decreased if appropriate for any patients that met dose reduction criteria. |
| BG005 | Total Title |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Patients Experiencing Treatment-emergent Adverse Events (TEAEs) in Part A of the Study | Evaluations were performed on the type, incidence and severity of TEAEs, graded according to Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03, following administration of givinostat for up to 6 cycles of treatment in Part A. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / treatment-emergent serious adverse event (TESAE) corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment. | The Safety (SAF) analysis set included all recruited patients who received ≥1 dose of study drug. | Posted | Count of Participants | Participants | 168 days (up to Cycle 6 Day 28 in Part A). |
|
|
| |||||||||||||||||||||||||||||||||||
| Primary | Number of Dose Limiting Toxicities (DLTs) After 1 Cycle in Part A of the Study | The MTD of givinostat was based only on Cycle 1 DLTs. A DLT was defined as the following drug-related toxicity:
At end of Cycle 1, for the third patient in each DL, the safety of the 3 patients treated for 1 cycle was reviewed and it was decided if the dose should be escalated or not. Results are reported as the number of patients with DLT events for Cycle 1 in Part A. | The MTD analysis set included all patients who experienced a DLT in Cycle 1 of Part A, or received ≥90% of study drug doses in Cycle 1 of Part A. | Posted | Number | participants | 28 days (up to Cycle 1 Day 28 in Part A). |
| |||||||||||||||||||||||||||||||||||||
| Primary | Number of Patients Experiencing TEAEs After 3 Cycles in Part B of the Study | Evaluations were performed on the type, incidence and severity of TEAEs, graded according to CTCAE v. 4.03, following administration of givinostat at the MTD for up to 3 cycles of treatment in Part B. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / TESAE corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment. | The SAF analysis set included all recruited patients who received ≥1 dose of study drug. | Posted | Count of Participants | Participants | 84 days (up to Cycle 3 Day 28 in Part B). |
| |||||||||||||||||||||||||||||||||||||
| Primary | Overall Response Rate (ORR) (i.e. Complete Response [CR] and Partial Response [PR]) After 3 Cycles in Part B of the Study | ORR, CR and PR following administration of givinostat at MTD for 3 cycles in Part B, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological European LeukemiaNet (ELN) response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. CR defined as:
PR defined as: Patients not fulfilling CR and
| The Intent-to-Treat (ITT) analysis set included all recruited patients who received ≥1 dose of study drug and from whom ≥1 post-baseline efficacy measurement was obtained. | Posted | Number | 95% Confidence Interval | percentage of participants | 84 days (up to cycle 3 Day 28 in Part B). |
| ||||||||||||||||||||||||||||||||||||
| Secondary | ORR After 3 Cycles and After 6 Cycles in Part A of the Study | ORR following administration of givinostat after 3 cycles and after 6 cycles in Part A, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological ELN response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. Analysis performed using the dataset for all Part A patients combined. | The ITT analysis set included all recruited patients who received ≥1 dose of study drug and from whom ≥1 post-baseline efficacy measurement was obtained. | Posted | Number | 95% Confidence Interval | percentage of participants | 84 and 168 days (up to Cycle 3 Day 28 and Cycle 6 Day 28 in Part A). |
|
| |||||||||||||||||||||||||||||||||||
| Secondary | ORR After 6 Cycles in Part B of the Study | ORR following administration of givinostat at the MTD for 6 cycles in Part B, reported as percentage of patients with a response. Response was evaluated according to the clinico-hematological ELN response criteria. If Investigator's clinical response assessment (taking into account the overall medical judgment of the specific patient's case) was not in agreement with exact application of the ELN response criteria, the Investigator's assessment superseded the mathematical application of these criteria and was used for analysis. | The ITT analysis set included all recruited patients who received ≥1 dose of study drug and from whom ≥1 post-baseline efficacy measurement was obtained. | Posted | Number | 95% Confidence Interval | percentage of participants | 168 days (up to Cycle 6 Day 28 in Part B). |
|
| |||||||||||||||||||||||||||||||||||
| Secondary | Number of Patients Experiencing TEAEs After 6 Cycles in Part B of the Study | Evaluations were performed on the type, incidence and severity of TEAEs, graded according to CTCAE v. 4.03, following administration of givinostat at the MTD for up to 6 cycles of treatment in Part B. Grades 1 through 5 were as follows: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life threatening or requiring hospitalisation; Grade 4: Life threatening consequences; Grade 5: Death related to AE. Results are reported as number of patients with TEAEs for each of the indicated categories. Definitions: drug-related TEAE / TESAE corresponded to reasonable suspicion that the TEAE / TESAE was associated with the use of the study drug, according to investigator assessment; discontinuation refers to discontinuation from treatment. Results are reported as number of patients with TEAEs for each of the indicated categories. | The SAF analysis set included all recruited patients who received ≥1 dose of study drug. | Posted | Number | participants | 168 days (up to Cycle 6 Day 28 in Part B). |
| |||||||||||||||||||||||||||||||||||||
| Secondary | Assessment of Maximum Plasma Concentration (Cmax) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study | Pharmacokinetic (PK) evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Cmax following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis. | The PK analysis set included all SAF patients with at least 1 PK assessment. Only patients with data available for analysis at each time point are presented. | Posted | Mean | Standard Deviation | nanograms per millilitre (ng/mL) | Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Assessment of Time to Maximum Plasma Concentration (Tmax) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tmax following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis. | The PK analysis set included all SAF patients with at least 1 PK assessment. Only patients with data available for analysis at each time point are presented. | Posted | Median | Full Range | hours | Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Assessment of Time of the Last Detectable Concentration (Tlast) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tlast following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis. | The PK analysis set included all SAF patients with at least 1 PK assessment. Only patients with data available for analysis at each time point are presented. | Posted | Mean | Standard Deviation | hours | Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Assessment of Area Under Plasma Concentration Versus the Time Curve up to the Last Detectable Concentration (AUClast) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUClast following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note: concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis. | The PK analysis set included all SAF patients with at least 1 PK assessment. Only patients with data available for analysis at each time point are presented. | Posted | Mean | Standard Deviation | ng*h/mL | Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Assessment of Area Under Plasma Concentration Versus the Time Curve in the Dosing Interval (0-12 Hours) (AUC0-12) of Givinostat and Metabolites (ITF2374 and ITF2375) in Part A of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUC0-12 following administration of givinostat for 1 cycle in Part A. PK calculations were performed by standard non-compartmental analysis and AUC0-12 was calculated using the linear trapezoidal rule. Results are reported for Cycle 1 Day 1 and Cycle 1 Day 28. Note:concentration data for ITF2374 (Cycle 1 Day 1 and Cycle 1 Day 28) across all dose groups and for ITF2375 (Cycle 1 Day 1) in the DL0 dose group of Part A were not available for PK analysis. | The PK analysis set included all SAF patients with at least 1 PK assessment. Only patients with data available for analysis at each time point are presented. | Posted | Mean | Standard Deviation | ng*h/mL | Blood samples were collected in Part A on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 1 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Assessment of Cmax of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Cmax following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis. | The PK analysis set included all SAF patients with at least 1 PK assessment. Only patients with data available for analysis at each time point are presented. | Posted | Mean | Standard Deviation | ng/mL | Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Assessment of Tmax of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tmax following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis. | The PK analysis set included all SAF patients with at least 1 PK assessment. Only patients with data available for analysis at each time point are presented. | Posted | Median | Full Range | hours | Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Assessment of Tlast of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of Tlast following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis. | The PK analysis set included all SAF patients with at least 1 PK assessment. Only patients with data available for analysis at each time point are presented. | Posted | Mean | Standard Deviation | hours | Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Assessment of AUClast of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUClast following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2375 (Cycle 1 Day 28) in the 50 mg b.i.d. dose group was not available for PK analysis. | The PK analysis set included all SAF patients with at least 1 PK assessment. Only patients with data available for analysis at each time point are presented. | Posted | Mean | Standard Deviation | ng*h/mL | Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Assessment of AUC0-12 of Givinostat and Metabolites (ITF2374 and ITF2375) in Part B of the Study | PK evaluation of givinostat and metabolites (ITF2374 and ITF2375) by assessment of AUC0-12 following administration of givinostat for 2 cycles in Part B. PK calculations were performed by standard non-compartmental analysis and AUClast was calculated using the linear trapezoidal rule. Following definition of the MTD in Part A, during Part B Cycle 1, givinostat was administered at 100 mg b.i.d. and during Part B Cycle 2 was administered at 100 mg, 75 mg and 50 mg b.i.d. (since dose reductions due to TEAEs were allowed from Cycle 2 onwards, as per protocol). Results are reported for Cycle 1 Day 1 and Cycle 2 Day 28 for the doses administered during Part B. Note: PK evaluation for the givinostat 75 mg and 50 mg b.i.d. dose groups for Cycle 1 Day 1 was not applicable (since all received givinostat 100 mg b.i.d.). Additionally, concentration data for ITF2374 (Cycle 1 Day 28) across all dose groups and for ITF2375 in the 50 mg b.i.d. dose group was not available for PK analysis. | The PK analysis set included all SAF patients with at least 1 PK assessment. Only patients with data available for analysis at each time point are presented. | Posted | Mean | Standard Deviation | ng*h/mL | Blood samples were collected in Part B on Cycle 1 Day 1: pre-dose and 2, 3 and 8 hours post-dose; and on Cycle 2 Day 28: pre-dose and 1, 2, 4 and 8 hours post-dose. |
|
168 days for Part A and 168 days for Part B (Cycle 1 through Cycle 6 for each phase of study; each cycle 28 days).
TEAEs are reported for Part A and Part B and include events with an onset on or after the first administration of study drug until the end of study visit (or 7 days after the last drug intake for any patient permanently discontinuing study treatment).
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Givinostat DL0 (50 mg b.i.d.) (Part A) | In Part A, 3 patients were assigned to receive givinostat by oral administration at DL0 (50 mg b.i.d.). Patients were treated for up to 6 cycles (28 days in each cycle). There were 3 DLs used during Part A; 50 mg b.i.d. (DL0) was the third DL to be administered. | 0 | 3 | 0 | 3 | 3 | 3 |
| EG001 | Givinostat DL1 (100 mg b.i.d.) (Part A) | In Part A, 3 patients were assigned to receive givinostat by oral administration at DL1 (100 mg b.i.d.). Patients were treated for up to 6 cycles (28 days in each cycle). There were 3 DLs used during Part A; 100 mg b.i.d. (DL1) was the initial DL to be administered. | 0 | 3 | 1 | 3 | 3 | 3 |
| EG002 | Givinostat DL1 Expanded (100 mg b.i.d.) (Part A) | Following initial assignment of 3 patients to DL1 in Part A, a further 3 patients were assigned to DL1 so this treatment group is referred to as "DL1 expanded" (patients received givinostat by oral administration at 100 mg b.i.d.). Patients were treated for up to 6 cycles (28 days in each cycle). There were 3 DLs used during Part A; 100 mg b.i.d. (DL1) was the initial DL to be administered. | 0 | 3 | 0 | 3 | 3 | 3 |
| EG003 | Givinostat DL6 (100 mg + 50 mg) (Part A) | In Part A, 3 patients were assigned to receive givinostat by oral administration at DL6 (100 mg in the morning and 50 mg in the evening, i.e. 12 hours after). Patients were treated for up to 6 cycles in (28 days in each cycle). There were 3 DLs used during Part A; 100 mg + 50 mg (DL6) was the second DL to be administered. | 0 | 3 | 1 | 3 | 3 | 3 |
| EG004 | Givinostat at MTD (100 mg b.i.d.) (Part B) | In Part B, patients were assigned to receive the starting dose of givinostat by oral administration at the MTD determined in Part A (i.e. 100 mg b.i.d.). Patients were treated for up to 6 cycles (28 days in each cycle). Based on evaluations performed as part of the visit procedures on Day 28 of each cycle up to Cycle 5 and/or in any necessary additional study visit, the givinostat dose was decreased if appropriate for any patients that met dose reduction criteria. | 0 | 35 | 2 | 35 | 35 | 35 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Myocardial infarction | Cardiac disorders | MedDRA20.1 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA20.1 | Systematic Assessment |
| |
| Thrombophlebitis | Vascular disorders | MedDRA20.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MedDRA20.1 | Systematic Assessment |
| |
| Haemolytic anaemia | Blood and lymphatic system disorders | MedDRA20.1 | Systematic Assessment |
| |
| Neutropenia | Blood and lymphatic system disorders | MedDRA20.1 | Systematic Assessment |
| |
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA20.1 | Systematic Assessment |
| |
| Thrombocytosis | Blood and lymphatic system disorders | MedDRA20.1 | Systematic Assessment |
| |
| Palpitations | Cardiac disorders | MedDRA20.1 | Systematic Assessment |
| |
| Hypothyroidism | Endocrine disorders | MedDRA20.1 | Systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Abdominal pain upper | Gastrointestinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Dry mouth | Gastrointestinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Dyspepsia | Gastrointestinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Faeces soft | Gastrointestinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Flatulence | Gastrointestinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Haemorrhoids | Gastrointestinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Asthenia | General disorders | MedDRA20.1 | Systematic Assessment |
| |
| Chest pain | General disorders | MedDRA20.1 | Systematic Assessment |
| |
| Early satiety | General disorders | MedDRA20.1 | Systematic Assessment |
| |
| Fatigue | General disorders | MedDRA20.1 | Systematic Assessment |
| |
| Oedema peripheral | General disorders | MedDRA20.1 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA20.1 | Systematic Assessment |
| |
| Hyperbilirubinaemia | Hepatobiliary disorders | MedDRA20.1 | Systematic Assessment |
| |
| Localised infection | Infections and infestations | MedDRA20.1 | Systematic Assessment |
| |
| Parainfluenzae virus infection | Infections and infestations | MedDRA20.1 | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA20.1 | Systematic Assessment |
| |
| Blood bilirubin increased | Investigations | MedDRA20.1 | Systematic Assessment |
| |
| Blood creatinine increased | Investigations | MedDRA20.1 | Systematic Assessment |
| |
| Blood lactate dehydrogenase increased | Investigations | MedDRA20.1 | Systematic Assessment |
| |
| Electrocardiogram qt prolonged | Investigations | MedDRA20.1 | Systematic Assessment |
| |
| Gamma-glutamyltransferase increased | Investigations | MedDRA20.1 | Systematic Assessment |
| |
| Weight decreased | Investigations | MedDRA20.1 | Systematic Assessment |
| |
| Decreased appetite | Metabolism and nutrition disorders | MedDRA20.1 | Systematic Assessment |
| |
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA20.1 | Systematic Assessment |
| |
| Hyperkalaemia | Metabolism and nutrition disorders | MedDRA20.1 | Systematic Assessment |
| |
| Hypocalcaemia | Metabolism and nutrition disorders | MedDRA20.1 | Systematic Assessment |
| |
| Iron deficiency | Metabolism and nutrition disorders | MedDRA20.1 | Systematic Assessment |
| |
| Bone pain | Musculoskeletal and connective tissue disorders | MedDRA20.1 | Systematic Assessment |
| |
| Chondrocalcinosis | Musculoskeletal and connective tissue disorders | MedDRA20.1 | Systematic Assessment |
| |
| Rheumatoid arthritis | Musculoskeletal and connective tissue disorders | MedDRA20.1 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA20.1 | Systematic Assessment |
| |
| Dysgeusia | Nervous system disorders | MedDRA20.1 | Systematic Assessment |
| |
| Head discomfort | Nervous system disorders | MedDRA20.1 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA20.1 | Systematic Assessment |
| |
| Hypoaesthesia | Nervous system disorders | MedDRA20.1 | Systematic Assessment |
| |
| Memory impairment | Nervous system disorders | MedDRA20.1 | Systematic Assessment |
| |
| Confusional state | Psychiatric disorders | MedDRA20.1 | Systematic Assessment |
| |
| Irritability | Psychiatric disorders | MedDRA20.1 | Systematic Assessment |
| |
| Acute kidney injury | Renal and urinary disorders | MedDRA20.1 | Systematic Assessment |
| |
| Chromaturia | Renal and urinary disorders | MedDRA20.1 | Systematic Assessment |
| |
| Chronic kidney disease | Renal and urinary disorders | MedDRA20.1 | Systematic Assessment |
| |
| Pelvic pain | Reproductive system and breast disorders | MedDRA20.1 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Dyspnoea exertional | Respiratory, thoracic and mediastinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA20.1 | Systematic Assessment |
| |
| Alopecia | Skin and subcutaneous tissue disorders | MedDRA20.1 | Systematic Assessment |
| |
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA20.1 | Systematic Assessment |
| |
| Erythromelalgia | Vascular disorders | MedDRA20.1 | Systematic Assessment |
| |
| Flushing | Vascular disorders | MedDRA20.1 | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA20.1 | Systematic Assessment |
| |
| Lymphoedema | Vascular disorders | MedDRA20.1 | Systematic Assessment |
| |
| Thrombosis | Vascular disorders | MedDRA20.1 | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Medical Expert | ITALFARMACO S.p.A. | +39 026443 258 | p.bettica@italfarmaco.com |
| SAP_000.pdf |
| Prot | Yes | No | No | Study Protocol | Jul 29, 2015 | Mar 18, 2019 | Prot_001.pdf |
| ID | Term |
|---|---|
| D011087 | Polycythemia Vera |
| D009196 | Myeloproliferative Disorders |
| D013920 | Thrombocythemia, Essential |
| D055728 | Primary Myelofibrosis |
| ID | Term |
|---|---|
| D019046 | Bone Marrow Neoplasms |
| D019337 | Hematologic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D001778 | Blood Coagulation Disorders |
| D013922 | Thrombocytosis |
| D001791 | Blood Platelet Disorders |
| D006474 | Hemorrhagic Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C575255 | givinostat |
| C502418 | givinostat hydrochloride |
Not provided
Not provided
Not provided
| Between 18 and 65 years |
|
| >=65 years |
|
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Drug-related TEAE |
|
| TESAE |
|
| Drug-related TESAE |
|
| Death due to any cause |
|
| Grade 3 TEAE |
|
| Grade 3 drug-related TEAE |
|
| Grade 4 TEAE |
|
| Grade 4 drug-related TEAE |
|
| Grade 5 TEAE |
|
| Discontinuation due to TEAE |
|
| Discontinuation due to drug-related TEAE |
|
| Discontinuation due to TESAE |
|
| Discontinuation due to drug-related TESAE |
|
In Part A, 3 patients were assigned to receive givinostat by oral administration at DL1 (100 mg b.i.d.). Patients were treated for up to 6 cycles (28 days in each cycle). There were 3 DLs used during Part A; 100 mg b.i.d. (DL1) was the initial DL to be administered. |
| OG002 | Givinostat DL1 Expanded (100 mg b.i.d.) (Part A) | Following initial assignment of 3 patients to DL1 in Part A, a further 3 patients were assigned to DL1 so this treatment group is referred to as "DL1 expanded" (patients received givinostat by oral administration at 100 mg b.i.d.). Patients were treated for up to 6 cycles (28 days in each cycle). There were 3 DLs used during Part A; 100 mg b.i.d. (DL1) was the initial DL to be administered. |
| OG003 | Givinostat DL6 (100 mg + 50 mg) (Part A) | In Part A, 3 patients were assigned to receive givinostat by oral administration at DL6 (100 mg in the morning and 50 mg in the evening, i.e. 12 hours after). Patients were treated for up to 6 cycles in (28 days in each cycle). There were 3 DLs used during Part A; 100 mg + 50 mg (DL6) was the second DL to be administered. |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|
|
|
| Participants |
|
|
|
|
| OG002 | Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set) | This dataset was used for PK analysis and included the patients who received givinostat at DL6 (100 mg in the morning and 50 mg in the evening) in Part A of the study and for whom PK data was available for analysis. |
|
|
| OG002 | Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set) | This dataset was used for PK analysis and included the patients who received givinostat at DL6 (100 mg in the morning and 50 mg in the evening) in Part A of the study and for whom PK data was available for analysis. |
|
|
| OG002 | Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set) | This dataset was used for PK analysis and included the patients who received givinostat at DL6 (100 mg in the morning and 50 mg in the evening) in Part A of the study and for whom PK data was available for analysis. |
|
|
| OG002 | Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set) | This dataset was used for PK analysis and included the patients who received givinostat at DL6 (100 mg in the morning and 50 mg in the evening) in Part A of the study and for whom PK data was available for analysis. |
|
|
| OG002 | Givinostat DL6 (100 mg + 50 mg) (Part A PK Analysis Set) | This dataset was used for PK analysis and included the patients who received givinostat at DL6 (100 mg in the morning and 50 mg in the evening) in Part A of the study and for whom PK data was available for analysis. |
|
|
| OG001 | Givinostat 75 mg b.i.d. (Part B PK Analysis Set) | This dataset was used for PK analysis and included patients who received givinostat at the reduced dose of 75 mg b.i.d. in Part B of the study and for whom PK data was available for analysis. This dataset only applied for PK analysis from Cycle 2 onwards (i.e. Cycle 2 Day 28). |
| OG002 | Givinostat 50 mg b.i.d. (Part B PK Analysis Set) | This dataset was used for PK analysis and included patients who received givinostat at the reduced dose of 50 mg b.i.d. in Part B of the study and for whom PK data was available for analysis. This dataset only applied for PK analysis from Cycle 2 onwards (i.e. Cycle 2 Day 28). |
|
|
| OG001 | Givinostat 75 mg b.i.d. (Part B PK Analysis Set) | This dataset was used for PK analysis and included patients who received givinostat at the reduced dose of 75 mg b.i.d. in Part B of the study and for whom PK data was available for analysis. This dataset only applied for PK analysis from Cycle 2 onwards (i.e. Cycle 2 Day 28). |
| OG002 | Givinostat 50 mg b.i.d. (Part B PK Analysis Set) | This dataset was used for PK analysis and included patients who received givinostat at the reduced dose of 50 mg b.i.d. in Part B of the study and for whom PK data was available for analysis. This dataset only applied for PK analysis from Cycle 2 onwards (i.e. Cycle 2 Day 28). |
|
|
| OG001 | Givinostat 75 mg b.i.d. (Part B PK Analysis Set) | This dataset was used for PK analysis and included patients who received givinostat at the reduced dose of 75 mg b.i.d. in Part B of the study and for whom PK data was available for analysis. This dataset only applied for PK analysis from Cycle 2 onwards (i.e. Cycle 2 Day 28). |
| OG002 | Givinostat 50 mg b.i.d. (Part B PK Analysis Set) | This dataset was used for PK analysis and included patients who received givinostat at the reduced dose of 50 mg b.i.d. in Part B of the study and for whom PK data was available for analysis. This dataset only applied for PK analysis from Cycle 2 onwards (i.e. Cycle 2 Day 28). |
|
|
| OG001 | Givinostat 75 mg b.i.d. (Part B PK Analysis Set) | This dataset was used for PK analysis and included patients who received givinostat at the reduced dose of 75 mg b.i.d. in Part B of the study and for whom PK data was available for analysis. This dataset only applied for PK analysis from Cycle 2 onwards (i.e. Cycle 2 Day 28). |
| OG002 | Givinostat 50 mg b.i.d. (Part B PK Analysis Set) | This dataset was used for PK analysis and included patients who received givinostat at the reduced dose of 50 mg b.i.d. in Part B of the study and for whom PK data was available for analysis. This dataset only applied for PK analysis from Cycle 2 onwards (i.e. Cycle 2 Day 28). |
|
|
| OG001 | Givinostat 75 mg b.i.d. (Part B PK Analysis Set) | This dataset was used for PK analysis and included patients who received givinostat at the reduced dose of 75 mg b.i.d. in Part B of the study and for whom PK data was available for analysis. This dataset only applied for PK analysis from Cycle 2 onwards (i.e. Cycle 2 Day 28). |
| OG002 | Givinostat 50 mg b.i.d. (Part B PK Analysis Set) | This dataset was used for PK analysis and included patients who received givinostat at the reduced dose of 50 mg b.i.d. in Part B of the study and for whom PK data was available for analysis. This dataset only applied for PK analysis from Cycle 2 onwards (i.e. Cycle 2 Day 28). |
|
|